Eisai Launches Acicept Jelly Formulation
This article was originally published in PharmAsia News
Tokyo-based Eisai Dec. 2 launched a jelly formulation of its blockbuster drug Aricept (donepezil) for Alzheimer's disease. The new formulation comes in three dosages: 3mg, 5mg and 10mg. Eisai hopes to maximize Aricpet product value through adding new formulations before the basic patent for the drug expires in November 2010. The company also launched a fine granule formulation. Eisai said the addition will make Aricept easier to take for senior AD patients who have difficulty swallowing. (Click here for more - Japanese language
You may also be interested in...
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.